Medivir AB News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

28.07.14	Medivir: Phase II COSMOS Study Results Published in The Lancet on World Hepatitis Day (Businesswire)
15.07.14	Medivir: U.S. FDA Has Granted Priority Review for OLYSIO® in Combination with sofosbuvir Supplementary New Drug Application (Businesswire)
15.07.14	Medivir: Continued strong market uptake for OLYSIO® during the second quarter 2014 (Businesswire)
10.06.14	Medivir: OLYSIO™ available soon in all Nordic countries for the treatment of adults with hepatitis C genotype 1 and 4 infection (Businesswire)
16.05.14	Medivir: Simeprevir approved in the European Union for the treatment of adults with hepatitis C genotype 1 and 4 infection (Businesswire)
08.05.14	Resolutions at the Annual General Meetings in Medivir on 8 May 2014 (Businesswire)
08.05.14	Medivir: Interim Report, January – March 2014* (Businesswire)
07.05.14	Medivir: a Supplemental New Drug Application Has Been Submitted to the U.S. FDA for Simeprevir in Combination with Sofosbuvir (Businesswire)
30.04.14	Medivir: Adasuve will now be launched in Sweden, Norway, Finland and Denmark (Businesswire)
15.04.14	Medivir: Good Market Uptake for Simeprevir During the First Quarter 2014 (Businesswire)
12.04.14	Medivir: Final Data from the Phase II COSMOS Study with Simeprevir in Combination with Sofosbuvir Presented at EASL (Businesswire)
07.04.14	Notice of Annual General Meeting of Medivir AB (publ) (Businesswire)
07.04.14	Medivir: Annual Report 2013 (Businesswire)
24.03.14	Medivir: New Simeprevir data will be presented at The International Liver Congress 2014 of the European Association for the Study of the Liver, (EASL) (Businesswire)
24.03.14	Medivir: Simeprevir has now been approved in Russia (Businesswire)
21.03.14	Medivir: Simeprevir receives positive CHMP opinion for the treatment of adults with chronic hepatitis C in the European Union (Businesswire)
14.03.14	Medivir: The Nomination Committee’s Proposal, with Reference to the Upcoming 2014 Annual General Meeting, for a New Board of Directors (Businesswire)
04.03.14	Medivir: SVR12 Results from a Phase IIa Study Evaluating Simeprevir and Daclatasvir in Hepatitis C Patients of Genotype 1 Have Been Presented (Businesswire)
24.02.14	Medivir: Financial Statement, 1 January – 31 December 2013* (Businesswire)
13.01.14	Medivir: Interim results (SVR4) from a phase II all-oral combination study of Simeprevir and Samatasvir (IDX719) for the treatment of hepatitis C (Businesswire)
12.12.13	Medivir: An all-oral phase IIa study combining Simeprevir, TMC647055 and JNJ56914845 in hepatitis C patients to be initiated (Businesswire)
10.12.13	Medivir: Simeprevir is now available for Hepatitis C patients in Japan, USA and Canada (Businesswire)
02.12.13	Medivir: HELIX-2, a Phase II All-Oral Combination Study of Simeprevir, TMC647055 and Samatasvir (IDX719) for the Treatment of Hepatitis C Has Been Initiated (Businesswire)
23.11.13	Medivir: Simeprevir Has Been Approved in the USA as a New Treatment for Hepatitis C (Businesswire)
21.11.13	Medivir: Interim Report, 1 January – 30 September 2013* (Businesswire)
20.11.13	Medivir: Simeprevir has been approved in Canada as a new treatment for hepatitis C (Businesswire)
04.11.13	Medivir: Results from the COSMOS Study with Simeprevir and Sofosbuvir in Cirrhotic and Non-Cirrhotic HCV Genotype 1 Patients Presented at AASLD (Businesswire)
02.11.13	Medivir Announces That New Simeprevir Data Will Be Presented at the AASLD Meeting (Businesswire)
24.10.13	Medivir: FDA Advisory Committee recommends approval of Simeprevir for combination treatment of genotype 1 chronic hepatitis C in adult patients (Businesswire)
22.10.13	Medivir: The regulatory process for Simeprevir in the U.S. (Businesswire)
18.10.13	Medivir announces data from two phase III studies with Simeprevir in hepatitis C subpopulations – HCV/HIV co-infected and genotype 4 infected patients (Businesswire)
14.10.13	Medivir Nomination Committee Appointed (Businesswire)
10.10.13	Medivir: MIV-247 Has Been Selected as a Candidate Drug and Enters Development for the Treatment of Neuropathic Pain (Businesswire)
09.10.13	Medivir: Positive results from a phase I study with MIV-711 for the treatment of osteoarthritis and other bone related disorders (Businesswire)
08.10.13	Medivir: Janssen Has Acquired an NS5a Replication Complex Inhibitor That Will Be Evaluated with Simeprevir in Future Clinical Development (Businesswire)
07.10.13	Medivir: Simeprevir data from COSMOS study in Hepatitis C patients will be presented as late-breaking presentation at AASLD (Businesswire)
01.10.13	Medivir Announces That Simeprevir Data Will Be Presented at the Upcoming AASLD Meeting (Businesswire)
18.09.13	Medivir Capital Markets Day on 10 October 2013 (Businesswire)
17.09.13	Medivir: The regulatory process in Japan for simeprevir (Businesswire)
06.09.13	Medivir: The Collaboration with Daewoong Pharmaceutical for the Development of the Hepatitis B Compound, MIV-210 Has Been Discontinued (Businesswire)
28.08.13	Medivir Announces Interim Results from Cohort 2 of the COSMOS Study Evaluating Simeprevir and Sofosbuvir in HCV Patients with METAVIR Scores F3-F4 (Businesswire)
22.08.13	Medivir: Interim Report, 1 January – 30 June 2013* (Businesswire)
15.08.13	Medivir Makes Strategic Decision to Focus Proprietary Hepatitis C R&D Efforts Exclusively on Nucleotide-Based Polymerase Inhibitors (Businesswire)
20.12.12	Medivir Announces Phase III Data for Simeprevir Demonstrating Efficacy and Safety in Genotype 1 Hepatitis C Patients (Businesswire)
13.12.12	Medivir announces initiation of the second cohort of the interferon-free phase II study combining Simeprevir and sofosbuvir for hepatitis C treatment (Businesswire)
20.11.12	Medivir: Interim Report, 1 January-30 September 2012* (Businesswire)
01.11.12	Medivir announces a phase II all-oral study of Simeprevir (TMC435) and VX-135 for the treatment of Hepatitis C to be conducted by Janssen and Vertex (Businesswire)
01.10.12	Medivir Announces That Simeprevir (TMC435) Data Will Be Presented at the Upcoming AASLD Meeting (Businesswire)
20.09.12	Medivir: A phase IIa interferon free combination hepatitis C trial of Simeprevir (TMC435) and TMC647055 will commence shortly (Businesswire)
05.09.12	Medivir Acquires Preclinical Antiviral Programs Including Hepatitis C and Prodrug Technologies (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Swisscom	527.00	2.33 %	K V
Holcim	95.34	1.21 %	K V
UBS Group	30.42	0.86 %	K V
Roche Hldg G	289.00	0.45 %	K V
Swiss Re	141.65	0.35 %	K V
Givaudan	3’850.00	-1.48 %	K V
Lonza Grp	603.80	-1.50 %	K V
Alcon	82.30	-1.53 %	K V
Geberit	508.00	-1.74 %	K V
Part Grp Hldg	1’386.00	-2.26 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Medivir AB

Aktien Top/Flop

Meistgelesene Nachrichten